Drugs / insulin isophane
insulin isophane
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01963728 Comparator | Nov 2013 → Apr 2015 | diabetes mellitus | Inova Health Care Services | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00346996 Comparator | May 2007 → Nov 2011 | type 1 diabetes mellitus | Lise Tarnow | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin isophane | “Because of this pattern, transplant patients may respond better to morning insulin isophane (intermediate acting) than to long-acting insulin glargine preparations.” NCT01963728 ↗ |
| Known as | isophane insulin | “Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and...” NCT01963728 ↗ |
| Known as | NPH insulin | “Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and...” NCT01963728 ↗ |
| Route | Subcutaneous | “for subcutaneous injection” NCT00346996 ↗ |